NCEL Company Profile and Key Details

NCEL has shown mixed momentum, losing -0.4% over the past week and -84.97% over the past quarter, though year-to-date performance is up 30.53%. Short-term trend indicators are mixed aligned (SMA20 4.3%, SMA50 11.59%, SMA200 -79.04%). The stock’s 14-day RSI is 54.44 (neutral), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -90.68% below its high and over 51.85% above its low. Average 10-day trading volume of 56.64 thousand shares is in line with the 3-month average of 57.87 thousand, indicating normal recent market interest.

NewcelX Ltd. generated EPS of -$17.34 over the past year. Five-year average earnings growth is 33.06%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $23.00. The high target offers 475.0% upside. The low target suggests 475.0% downside. The mean target is $23.00. This offers 475.0% upside.

NewcelX Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.48. This means the shares are trading above this model’s fair value.

NewcelX Ltd. (NASDAQ:NCEL) closed at $4.00 USD, losing -$0.19 (-4.53%) from the previous close of $4.19. The stock is currently mid-range between its 52-week high and low $1.83 and $28.03. With a market capitalization of about $1.80 million, NewcelX Ltd. is classified as a micro-cap and shows market-like volatility (beta ~0.92). Key stats such as the average daily volume over the past year has been around 58.64 thousand shares, volume is running light vs its 52-week average. Headquartered in Zurich, None, NewcelX Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ronen Twito, the company employs approximately 11 people and listed since October 24, 2025. NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions.

Our AI price prediction model suggests that NewcelX Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.75%, with price expected at $4.63 by July 27, 2026, within a range of $4.48 to $4.80 3-Month Outlook: Projected fall of -28.5%, reaching $2.86 by October 08, 2026, with a range of $2.76 to $2.93. 1-Year Outlook: Projected gain of 223.5%, with price at $12.94 by July 13, 2027, within a range of $12.75 to $13.11.

NewcelX Ltd. (NASDAQ:NCEL) shares are up 30.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NewcelX Ltd. trading at a premium to the broader market with a P/E of -0.43. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $23.00, suggesting 475.0% upside. Our AI forecast model points to short-term strength (15.75% over two weeks), a medium-term fall (-28.5% over three months), and a longer-term gain (223.5% over one year), with expected trading ranges indicating moderate volatility.

NewcelX Ltd. trades at a P/E ratio of -0.43, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.85 suggesting the stock is closer to book value. The P/FCF stands at -0.86, also above market averages.